

**AMENDMENTS TO THE CLAIMS**

**This listing of the claims replaces all prior versions of the claims in the application.**

---

1.-20. (Canceled)

21. (Previously presented) An isolated polypeptide selected from the group consisting of:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:5;
- b) a polypeptide comprising a naturally-occurring amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:5, said polypeptide having apoptotic activity;
- c) a biologically-active fragment of at least 30 contiguous amino acid residues of a polypeptide having the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:5, said fragment having apoptotic activity; and
- d) an immunogenic fragment of at least 30 contiguous amino acid residues of a polypeptide having the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:5.

22. (Previously presented) An isolated polypeptide of claim 21, having a sequence of SEQ ID NO:3.

23. (Canceled)

24. (Withdrawn) A method for producing a polypeptide of claim 21, the method comprising:

- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 21; and
- b) recovering the polypeptide so expressed.

25. (Withdrawn) A method of claim 24, wherein the polypeptide has the sequence of SEQ ID NO:3 or SEQ ID NO:5.


26. (Canceled)

27. (Previously presented) A composition comprising a polypeptide of claim 21 and a pharmaceutically acceptable excipient.

28. (Previously presented) A composition of claim 27, wherein the polypeptide has the sequence of SEQ ID NO:3 or SEQ ID NO:5.

29. (Withdrawn) A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 21, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 21 to a compound; and
- b) detecting agonist activity in the sample.

 30. (Withdrawn) A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 21, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 21 to a compound; and
- b) detecting antagonist activity in the sample.

31.-40. (Canceled)

41. (Withdrawn) A method of screening for a compound that specifically binds to the polypeptide of claim 21, said method comprising the steps of:

- a) combining the polypeptide of claim 21 with at least one test compound under suitable conditions; and
- b) detecting binding of the polypeptide of claim 21 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 21.

42. (Withdrawn) A method of screening for a compound that modulates the activity of the polypeptide of claim 21, said method comprising:

- a) combining the polypeptide of claim 21 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 21;
- b) assessing the activity of the polypeptide of claim 21 in the presence of the test compound; and
- c) comparing the activity of the polypeptide of claim 21 in the presence of the test compound with the activity of the polypeptide of claim 21 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 21 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 21.

ε'4

43. (Previously presented) An isolated polypeptide of claim 21, having a sequence of SEQ ID NO:5.

44. (Previously presented) An isolated polypeptide of claim 21 comprising a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:3.

45. (Previously presented) An isolated polypeptide of claim 21 comprising a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:5.

---